Amgen Inc. (BIT:1AMGN)

Italy flag Italy · Delayed Price · Currency is EUR
255.05
-1.95 (-0.76%)
At close: Jul 18, 2025, 5:30 PM CET
-0.76%
Market Cap140.04B
Revenue (ttm)31.57B
Net Income (ttm)5.49B
Shares Outn/a
EPS (ttm)10.12
PE Ratio25.51
Forward PE14.76
Dividend6.30 (2.47%)
Ex-Dividend DateMay 15, 2025
Volume257
Average Volume104
Open257.55
Previous Close257.00
Day's Range255.00 - 257.60
52-Week Range233.00 - 337.65
Betan/a
RSI59.90
Earnings DateAug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 28,000
Stock Exchange Borsa Italiana
Ticker Symbol 1AMGN
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD Financial Statements

News

There is no news available yet.